To evaluate the therapeutic efficacy of Stronger Neo-Minophagen C (SNMC) in patientswith chronic liver diseases, a multicenter prospective study was performed in Beijing, China.A total of 109 patients were treated with SNMC intravenous injection and SNMC tablets (Minophagen Pharmaceutical Co., Tokyo, Japan). They responded to the treatment with marked effective rate of 66% and overall effective rate of 75%. SNMC was shown to lower serum ALT and AST levels shortly after the administration, especially for the patients with higher serum levels. Serum bilirubin was reduced simultaneously, and metabolism of protein was improved. SNMC was proved to be safe with minimal side effects.
更多
- Severe autoimmune hemolytic anemia in a patient with chronic hepatitis C
- APASL2006中文版
- PROSPECTIVE ASSESSMENT OF THE INCIDENCE OF INFECTIONS DURING PEGYLATED INTERFERO
- A Long-Term Glycyrrhizin Injection Therapy Reduces Hepatocellular Carcinogenesis
- Glycyrrhizin in Chronic Hepatitis C Patients
- Therapeutic effects of stronger neo-minophagen C at different doses on chronic
- Therapeutic effects of Stronger Neo-Minophagen C (SNMC) in patients with chronic
- Randomized clinical trial with SNMC in Chin-BE Wang-ok
- The long term efficacy of glycyrrhizin in chronic hepatitis C patients
- Hepatitis C viral infection